

Out. number: 194-00-66/07.12.2023

NOTIFICATION
according to Art. 111 para. 6 of the LPA for repurchase of shares

Sofia, Bulgaria, December 7, 2023 - Pursuant to the requirements of Art. 100t of the Law on Public Offering of Securities, "**Sopharma**" AD (SFA: BSE AD, SPH: Warsaw Stock Exchange) announces that on the basis of Art. 187b of the Commercial Law and Art. 111, para. 5 and para. 6 of the Law on Public Offering of Securities and in connection with the decision of the General Meeting of Shareholders of the company, held on 4 August 2023, and the decision of the Board of Directors of the company from 7 December 2023, "Sopharma" AD notifies that the company intends to buy back treasury shares within the limit according to Art. 111, para. 5 of the Law on Public Offering of Securities, as follows:

- Number of shares subject to redemption – 200,000 (two hundred thousand) shares;
- Buy-back price – BGN 6.10 for one share of the company's capital;
- Purchase date: 8 December 2023;
- Licensed investment intermediary to whom the purchase order was given – “First Financial Brokerage House” AD

/Signature/

Pelagia Viatcheva

Investor Relations Director

Information about the company

Sopharma AD

90 years of tradition and modernity - contemporary production, European standards and quality, best practices in the field of corporate and social responsibility.

Sopharma AD is the most successful Bulgarian company after the privatization, as from 2000 to today, the company realized 10 times growth in market capitalization and 25 times revenue growth. Over the past 10 years, Sopharma AD has been a leader in the pharmaceutical sector in Bulgaria.

Sopharma AD produces active substances and medicinal products; conducts activities related to development and implementation in the field of phytochemistry, chemistry and pharmacy, provides services related to production and other.

With 9 pharmaceutical plants in the country and the only ampoule factory in Bulgaria the company produces 3 billion tablets, 20 million syrup forms, has an authorization for over 200 generic products, 15 traditional products, 12 of which are plant-based, and uses more than 1500 tons of medicinal plants in its products.

Sopharma AD has an active and key role in raising the standard of living, in making people healthier, happier and protected. Sopharma AD is constantly investing in new technologies, innovations and research. The company maintains a dialogue with all players in the pharmaceutical industry and strives to contribute to improving the healthcare sector.

Sopharma Group

Sopharma Group is a vertically integrated healthcare business that operates in important health related sectors such as pharmaceuticals, hospital supplies, pharmaceutical products distribution and many others.